Articles from Genomind

Genomind, a leader in precision medicine and pharmacogenomic (PGx) testing, today announced it has been awarded a contract to support the Defense Health Agency’s (DHA) Research & Engineering (R&E) Directorate. The project, “Implementing and Assessing Pharmacogenomics for U.S. Active-Duty Service members,” is funded by the Congress through the FY24 Department of Defense Appropriations Act.

Genomind, a leader in medication management and personalized medicine through pharmacogenetics (PGx), is proud to announce the release of its innovative Patient Report. This new report empowers patients with easy-to-understand insights about how their genetics influence their body’s response to many medications. By making this information more accessible, the report fosters better collaboration between patients and healthcare providers, ensuring all parties are confident and informed about their treatment plans. The new Patient Report complements Genomind’s existing Neuropsych Report and Express Report already utilized by providers – creating an unmatched reporting suite for all audiences.

Genomind, a provider of population health management solutions and genetic testing for medication management, has partnered with Shore Quality Partners (SQP), an Accountable Care Organization (ACO) serving 28,000 Medicaid members of Somers Point, NJ and surrounding communities.

An innovative population health approach from Genomind was highlighted in a peer-reviewed publication titled, “Predicting Drug-Drug and Drug-Gene Interactions in a Community Pharmacy Population” published in the latest issue of the American Journal of Managed Care (AJMC). The article was co-authored by Stephen Saklad, PharmD, of the University of Texas at Austin and other Genomind colleagues.

Genomind, a provider of genetic testing and population health management solutions for medication management, has partnered with Parkview Physicians Group – Psychiatry in Fort Wayne, Indiana, to complete an interface for laboratory orders and results with Parkview’s Epic electronic health record (EHR) system.

Cosán, a provider of technology-driven preventative care services for older adults and the physicians that support them, and Genomind, a leading precision healthcare company, have partnered to fill an existing gap in aging adult care management by providing Cosán’s network of physicians with Genomind’s integrated precision medication management platform. The platform will provide insights that will help Cosán to achieve the best outcomes for their patient population, prevent adverse drug events and reduce avoidable costs of medication mismanagement.

Genomind®, a leading precision healthcare company, has named David Nash, MD, MBA the newest member of its Scientific Advisory Board (SAB).

Harmony United Psychiatric Care, a leading multi-city behavioral health practice and Genomind®, the leader in comprehensive digital mental health solutions, are teaming up to provide the newest tools for precision mental health services in Florida. The mental health crisis has worsened during the pandemic and the need for more access and new tools has never been greater. In fact, according to the Kaiser Family Foundation, about 4 in 10 adults in the U.S. have reported symptoms of anxiety or depressive disorder during the pandemic, up from one in ten adults who reported these symptoms from January to June 2019.

Audacy announced a multiplatform partnership with mental health innovator Genomind. This breakthrough partnership taps into Audacy’s influencers and Genomind’s personalized genetic insights to bring mental health conversations into the mainstream.

Professional basketball player Kevin Love is continuing his public crusade advocating for mental health and wellness by partnering with Genomind®, a leading mental health company that has been working with mental health professionals for more than a decade. The company’s Professional PGx Express™ test evaluates variants of 24 genes, and is designed to help mental health providers select effective, well tolerated medications at the right doses in order to reduce the costly and potentially tragic trial and error that is so often seen with medications used for mental health.